Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04686305 · ClinicalTrials.gov registry record · Phase 1

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

A Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
244
Enrollment target
20
Study locations

NCT04686305 is a Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 244 participants. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04686305, a Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
244 participants
Enrollment target
20
Study locations

Study Summary

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

Conditions Studied

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • BIOLOGICAL Durvalumab
  • DRUG T-DXd

Study Locations (20)

Other

  • Research Site - Adelaide
  • Research Site - Heidelberg
  • Research Site - Nedlands
  • Research Site - Edegem
  • Research Site - Barretos
  • Research Site - Porto Alegre
  • Research Site - São Paulo

California

  • Research Site - Duarte
  • Research Site - Newport Beach
  • Research Site - Orange
  • Research Site - Santa Rosa

New York

  • Research Site - Buffalo
  • Research Site - New York
  • Research Site - The Bronx

Kansas

  • Research Site - Westwood

Maryland

  • Research Site - Baltimore

Michigan

  • Research Site - Detroit

Texas

  • Research Site - Houston

Virginia

  • Research Site - Fairfax

Trial Details

FieldValue
Enrollment Target 244 participants
Start Date 2021-03-09
Est. Completion 2027-06-30
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04686305

The ClinicalTrials.gov registry entry for NCT04686305 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced or Metastatic Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04686305 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT04686305 about?

NCT04686305 is a clinical study titled "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC". DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

What is the current status of trial NCT04686305?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 244 participants. The study started on 2021-03-09. Estimated completion is 2027-06-30.

What conditions does trial NCT04686305 study?

This clinical trial studies the following conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT04686305?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Durvalumab (BIOLOGICAL), T-DXd (DRUG).

Who is sponsoring clinical trial NCT04686305?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04686305 being conducted?

This trial has 20 study locations across California, Kansas, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.